Sustainability Accounting Standards Board (SASB)

SASB is an independent, standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on material environmental, social and governance (ESG) factors.

The table below summarizes how our existing reporting aligns with the recommended metrics for the Biotechnology & Pharmaceuticals Standard within the Health Care sector, and where this information can be found on this site.

Topic/codeAccounting metric Location
Safety of clinical trial participants
210a.1Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials Clinical Research
Quality & Safety Standards
Product & Patient Safety
Clinical Trials website
210a.2Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: Voluntary Action Indicated (VAI) and Official Action Indicated (OAI) Clinical Research
Clinical Trials website
210a.3Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries Not reported.
Access to medicines
240a.1Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index Access to Health Overview
Affordability
HIV/AIDS
Infectious Diseases
Philanthropy
MECTIZAN Donation Program
Medical Outreach Program
Product Registration
Vaccines
Women's Health
240a.2List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) Product Registration
Affordability and pricing
240b.1Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period Not reported.
240b.2Percentage change in: average list price and average net price across U.S. product portfolio compared to previous year Affordability
240b.3Percentage change in: list price and net price of product with largest increase compared to previous year Affordability
Drug safety
250a.1List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database FAERS MedWatch
250a.2Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System FAERS MedWatch
250a.3Number of recalls issued, and total units recalled FAERS MedWatch
Quality & Safety Standards
250a.4Total amount of product accepted for takeback, reuse, or disposal Not reported.
250a.5Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type Not reported.
Counterfeit drugs
260a.1Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting Manufacturing & Supply
Product Integrity
Quality & Safety Standards
Sourcing & Supplier Relations
260a.2Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products Product Integrity
Not reported.
260a.3Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products Not reported.
Ethical marketing
270a.1Total amount of monetary losses as a result of legal proceedings associated with false marketing claims Sales & Marketing Practices
270a.2Description of code of ethics governing promotion of off-label use of products Sales & Marketing Practices
Employee recruitment, development and retention
330a.1Discussion of talent recruitment and retention efforts for scientists and research and development personnel Discovery & Invention
Learning & Development
330a.2Voluntary and involuntary turnover rate for: executives/senior managers, mid-level managers, professionals, and all others Engaging Our Employees
Supply chain management
430a.1Percentage of entity's facilities and Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients Not reported.
Business ethics
510a.1Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery Not reported.
510a.2Description of code of ethics governing interactions with health care professionals Code of Conduct
Compliance
Engaging with Health Care Professionals
Sales & Marketing Practices
Activity metrics
000.ANumber of patients treated Medical Outreach Program
Supporting Our Communities
000.BNumber of drugs in portfolio, and in research and development (Phases 1-3) Pipeline